zinostatin and Acute-Disease

Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Clinical Trials as Topic; Diphenhydramine; Drug Evaluation; Female; Humans; Infusions, Parenteral; Leukemia; Male; Middle Aged; Zinostatin

Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Male; Methotrexate; Middle Aged; Prednisolone; Vincristine; Zinostatin

An analysis of prognostic factors was performed on a series of 50 adult patients with acute leukemia, treated in our department in the Tokai university Hospital between July, 1975 and June, 1980. The diagnosis was made in all cases on the basis of May-Grünwald-Giemsa-stained smears of peripheral blood and bone marrow. The patients were treated with two successive protocols. One course of induction chemotherapy consisted of 40 units/kg/day of neocarzinostatin, 1.2-1.6 mg/kg/day of cytosine arabinoside, 0.6-0.8 mg/kg/day of daunorubicin and 0.8-1.6 mg/kg/day of prednisolone on days 1-4 for acute nonlymphocytic leukemia, and the other consisted of 0.04 mg/kg/day of vincristine on day 1, 0.6-0.8 mg/kg/day of daunorubicin on days 1-4, 0.8-1.6 mg/kg/day of prednisolone on days 1-4 for acute lymphocytic leukemia. Consolidation and intensification therapies were given every 1-2 months after complete remission, and the protocols were basically the same as those of the induction therapy. Maintenance therapy consisted of 1.2-1.6 mg/kg/day of cytosine arabinoside, twice a week or 2 mg/kg/day of 6 MP orally. Risk factor leading to poor prognosis of acute leukemia were considered to be (1) advanced age (older than 50 years, P less than 0.05), (2) M5 (monocytic leukemia), (3) thrombocytopenia (less than 50,000 cmm-1), and (4) chromosome abnormalities of blast cells.

Topics: Acute Disease; Adolescent; Adult; Aged; Chromosome Aberrations; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prednisolone; Prognosis; Vincristine; Zinostatin

Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Zinostatin

Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin

Topics: Acute Disease; Adolescent; Adult; Aminobiphenyl Compounds; Antineoplastic Agents; Asparaginase; Bone Marrow; Cell Survival; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukocyte Count; Male; Mercaptopurine; Mesylates; Methotrexate; Middle Aged; Neutrophils; Prednisolone; Time Factors; Zinostatin

Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin

Topics: Acute Disease; Antibiotics, Antineoplastic; Drug Evaluation; Humans; Leukemia; Middle Aged; Remission, Spontaneous; Zinostatin

Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Female; Humans; Infant; Leukemia; Male; Middle Aged; Zinostatin

Topics: Acute Disease; Antibiotics, Antineoplastic; Drug Therapy, Combination; Humans; Leukemia; Middle Aged; Zinostatin